WE GIVE SHAREHOLDERS A VOICE
Levi & Korsinsky, LLP announces that a DPLO class action lawsuit has been filed on behalf of investors who purchased Diplomat Pharmacy, Inc. (DPLO) securities between February 26, 2018 and February 21, 2019. For more on the DPLO Lawsuit please contact us today.
According to the Diplomat Pharmacy, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Diplomat Pharmacy, Inc. you have until April 25, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.